Active — Not RecruitingNot Applicable

A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil

Brazil1,006 participantsStarted 2023-04-10

Plain-language summary

The primary reason of this study is to observe current and past treatment in adult participants receiving Vedolizumab, intravenous (IV) or subcutaneous (SC), for IBD in Brazil. There is no treatment involved in this study, this is only an observational review of past and ongoing treatment data relating to Vedolizumab treatment for IBD (including Ulcerative Colitis \[UC\] and Crohn's Disease \[CD\]).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: • Who participated or who will participate in the "Entre Nós" program and participant who consent to participate in the study. Exclusion Criteria • No exclusion of participants is expected in the present study and the quality of the data relies in participant reported outcomes for the "Entre Nós" program.

What they're measuring

Number of Participants With Vedolizumab Treatment Persistence for Conventional Therapy and Advanced Therapies

Timeframe: Up to approximately 9 years

Trial details

NCT IDNCT05626088

SponsorTakeda

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-12-27

View on ClinicalTrials.gov More Ulcerative Colitis trials